arrow
W

William Tillett

University of Bath
H指数:32
被引数:4,062

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bimekizumab showed sustained and consistent efficacy in patients with active psoriatic arthritis at 2 years regardless of prior TNF-inhibitor status: update from the Phase 3 BE OPTIMAL and BE COMPLETE trials

Bimekizumab在2年时对活动性银屑病关节炎患者显示出持续且一致的疗效,且与既往TNF抑制剂使用状态无关:来自III期BE OPTIMAL和BE COMPLETE试验的更新。

2025-04-280
PRE
Bimekizumab-treated patients with active psoriatic arthritis showed sustained improvements in pain and fatigue: up to 2-year results from two Phase 3 studies

接受Bimekizumab治疗的具有活动性银屑病关节炎的患者在疼痛和疲劳方面显示出持续的改善:两项III期研究的2年结果。

2025-04-280
PRE
Early (3-month) and maintained (12-month) comparative effectiveness of five different classes of advanced therapies in a large multinational cohort of real-world psoriatic arthritis patients

早期(3个月)和维持期(12个月)五种不同类别先进疗法在大型多国真实世界银屑病关节炎患者队列中的比较疗效

2025-04-280
PRE
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

bimekizumab治疗的活动性银屑病关节炎患者达到临床疾病控制标准与患者报告结局的关联: 两项III期研究的结果

2024-11-110
OAAI